see them as providers of factual data and of references to published papers on their products. Most firms scan the world's literature, using either their own staff or a commercial information service, and store the references in their well-run data bases. If they made these available to the drug information services, they would be making a valuable contribution to the work of the health care professions and perhaps be saving public expenditure on the provision of duplicate services.
It is my contention that: (1) There is a need by the health care professions for unbiased information on drugs.
(2) Whilst much information can continue to be provided locally, some enquiries will require the sophisticated services which can only be provided by those skilled in data collection or its interpretation. (3) If advances in our knowledge are to be cofnmunicated to those who can implement them for the benefit of our patients, then there should be active dissemination of information. I am sure that drug information services, as I have briefly described them, are the best means to meet these needs. Both pharmacists and clinical pharmacologists have been providing their medical, dental, nursing and pharmaceutical colleagues with information about drugs for many years. Initially this was given on an informal basis, but the increasing complexity of modern drug therapy has led to demands for a more organized service.
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In the Northern Region we have established a clinical drug information service aimed at pro-viding medical colleagues with advice on all aspects of clinical pharmacology, pharmacokinetics, toxicology and therapeutics. Since May 1975 this service has been offered on a twenty-four-hour basis, with a duty pharmacologist available at any time of day or night. We will use our accumulated experience over the first year (Davies et al. 1976) to answer three fundamental questions: (1) Is there a need for drug information units within the National Health Service? (2) What are the logistics of their operation? (3) Is a clinical component desirable or necessary?
In the first twelve months of its operation, the Northern Region Clinical Drug Information Service (CDIS) was contacted on 404 occasions by telephone and 47 by post. Of these enquiries 87.6 % came from within the region. Although we had anticipated that the CDIS would be used exclusively by doctors, 12.2 % of enquiries were from paramedical colleagues (pharmacists and nurses), and 2.4 % from public services (mainly the police and the fire service). There is little doubt, therefore, that there is a demand for the type of service we have provided.
No less than 40 % of our enquiries were received between 5.00 p.m. and 9.00 a.m., and for this reason we regard twenty-four-hour availability as essential. Three-quarters of the enquiries we have received can be answered by experienced clinical pharmacologists either from memory, or by reference to basic texts or information sheets prepared locally. The remainder require extensive bibliographic searches, and since this is time consuming and complicated, assistance from information scientists is essential. Such personnel could be either librarians with wide knowledge of medical and pharmacological terminology, or pharmacists with training in librarianship.
Few of our enquirers were seeking purely factual information. Most (78.4 %) needed clinical pharmacological advice on the management of a specific case which usually involved discussing the possible benefits and hazards of one or more courses of action, taking into account the patient's present and past medical history. Such enquiries can be satisfactorily handled only by individuals with a medical qualification, clinical training and special expertise in pharmacology. Indeed, our experience suggests that doctors working full time in the information services, by removing themselves from active participation in clinical medicine, would inevitably diminish their capacity to advise their colleagues. At present our service has insufficient pharmaceutical expertise; this inevitably limits its scope, and we are currently reconstructing it so that both pharmacy and clinical pharmacology are adequately represented. In conclusion, therefore, our experience indicates that although drug information units are clearly needed within the Health Service, they require adequate supporting staff, and that both clinical pharmacology and pharmacy are essential ingredients. Miss Pamela Buckland (CIBA Laboratories, Horsham, Sussex) Drug Information Centres: an Industry View A drug information centre in industry can range from one person with very limited facilities to a large department using highly sophisticated techniques. In a few cases they are sufficiently large to be divided into a group dealing with purely internal documentation requirements, and another group dealing with medical information, as an extension of the medical services function. In most companies such units are part of the research or medical departments but in some, and particularly when they are large, they are responsible to technical servicing management.
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Our department is not divided in this way, and we provide a documentation back up which supports the fundamental research and development programmes as well as the marketing, clinical research and medical services functions; for all these groups we provide an access point to the published literature. As far as the fundamental research programme is concerned this is generally the extent of our involvement, but with a continuing commitment; some of the other functions, however, require an interpretative service, such as the evaluation of equivocal literature. We also provide a medical information service for enquiries from outside the company: from members of the medical, pharmaceutical and allied professions, as well as from academic institutes. Such enquiries come from the most senior to the most junior members of the professions, and are extremely wide ranging in nature.
To be of value the information given must be accurate, factual, professionally sound and quickly provided. Where necessary the information officer must be prepared to take an interpretative role; to do this and to maintain a high standard, one must have access to comprehensive data resources on one's own and comparative products, as well as an efficient retrieval system which may be manual or computerized. Broadly speaking, this information can be divided into two categories: 'active' and 'passive'. Active information is basic information on the proper usage of company products and on their use in unusual circumstances, either proper or improper. Generally, this type of information is required speedily, frequently in an emergency, and it must, therefore, be accurate and succinct. Passive information is more detailed information, not normally required for routine use, where the breadth and depth of the search are of paramount importance. This type of information is more likely to be required by clinical investigators, or for academic research projects using company products. Many of these information commitments are of an ongoing nature, for example, our department has for some time been collaborating with a group working in the field of hypertension associated with pregnancy.
Value of Drug Information Centres in Industry Drug information centres in industry have access to all the detailed knowledge accumulated from the time a drug was first developed: they have the key to information in the published literature, the knowledge of unpublished documentation, records of usage in unusual circumstances and, very important, access to the relevant experts. It is this breadth and depth of information that makes the industrial information centre unique for its own products; often what is an unusual, once-in-alifetime event to a particular practitioner has happened to others, and relevant data, filed away in the information centre, can be retrieved easily should the need arise. One of the major assets of information services in the industry, certainly as far as large companies are concerned, is the wide coverage of the scientific literature; there are hundreds of possibly relevant journals published in many languages and, for example, my own company counts on having about 95 % coverage of them, the information gleaned then being made available to all subsidiaries.
It is not generally realized that in many large companies the information service is available twenty-four hours a day, seven days a week. Any user can contact the company out of hours; our telephone recording machine is cleared every hour, and the medical information staff are contacted if required. Any professional person can use the resources of the department directly, to amplify his knowledge, to reassure himself or to confirm information given to him by a third party. Moreover, company drug information units are often aware of work in progress or still unpublished both within and outside the company, though discretion may be needed in deciding whether and how to use it if it is relevant to the problem on hand.
People working in drug information in industry have a detailed knowledge of a limited number of drugs and they are, therefore, very much aware of what facts need to be established before any query
